Follicular lymphoma (FL) represents 20-25% of all nonHodgkin's lymphomas. Although response rate to first-line chemotherapy is high, most patients ultimately relapse. After the first relapse, each subsequent therapy can only obtain a remission shorter than the previous. 1 The use of high-dose therapy (HDT), hematopoietic progenitor cells (HPCs) transplantation and rituximab at relapse has been shown to improve outcome, with longer OS 2 than with conventional chemotherapy. Positive results have been reported recently from prospective trials 3 and registry studies, 4 but follow-up is short 3 or details of therapy are missing. 4 Only one group has published data from a randomized study. 5 However, this trial was performed in the 'pre-rituximab' era, HPCs were ex vivo purged and were not subjected to molecular analysis. In addition, there has been concern about toxicity of the conditioning regimen with a significant increase of secondary tumors and myelodysplastic syndromes after TBI, despite a plateau in remission duration curve. 6 Therefore, additional survival data and longer follow-up are needed to assess the role of HDT, HPC transplantation and rituximab for in vivo purging and therapy in relapsed FL (rFL). In addition, clinical and molecular data have to be used to tailor a response-adapted therapy to lessen toxicity.
From 1997 to 2008, we performed rituximab-supplemented HDT and HPC transplantation 7 with in vivo purged HPCs in 36 consecutively enrolled, unselected patients with rFL (Table 1) , representing more than 90% of all relapsed patients seen at our Institution; only four patients were not treated with this therapy because of older age (465 years). Minimal residual disease (MRD) was assessed by PCR. Over the past few years, the schedule of HDT 7 has been slightly modified mainly to decrease toxicity and to improve safety. After the initial standard-dose phase (2-3 cycles of an anthracycline-containing regimen or DHAP chemotherapy), all patients received high-dose CY (HD-CTX, 7 g/m 2 ), 2 doses of rituximab (375 mg/m 2 ) and underwent HPC harvest. After HD-CTX, all patients were treated with high-dose cytarabine (HD-araC, 1.5-2 g/m 2 every 12 h for 5-6 consecutive days), 2 doses of rituximab, and underwent a second HPC harvest. Except for patients obtaining clinical (CR) and molecular (MR) remission after HD-araC, who received no further treatment and proceeded directly to the myeloablative phase, the remaining patients received one more cycle of therapy as detailed in Table 1 before the myeloablative phase. Apart from HD-CTX, each therapy was followed by reinfusion of a small amount of HPCs (2 Â 10 6 CD34 þ cells/kg body weight). After conditioning with either BEAM or mitoxantrone plus melphalan, all patients were transplanted: 34 of 36 (94%) patients were transplanted with MRD-negative HPCs (45 Â 10 6 CD34 þ cells/kg body weight). No probe was available for one patient, and one was transplanted with MRD-positive HPCs. HPC transplantation was followed a month later by 2 final doses of rituximab. No. of death 10 28
Causes of death All patients were successfully mobilized after HD-CTX and HD-araC. After HD-CTX, we were able to harvest MRD-negative HPCs in 24 of 35 evaluable patients (68%), while after HD-araC 34 of 35 evaluable patients (97%) harvested MRD-negative HPCs. After completion of the entire program, all patients achieved CR and 34 of 35 evaluable patients (97%) were in MR. With a median follow-up of 71 months (range 5-144), 26 of 36 (72%) patients remain in CR and all 26 (100%) evaluable patients in MR. Five patients (14%) relapsed clinically, two of whom are now in CR after allogeneic BMT, and three died of progressive disease. Toxicity consisted mainly of infectious episodes (Table 1 ). Ten patients (28%) died (Table 1) . After more than 10 years, median OS and PFS have not been reached, and the 12-year values are 70 and 76%, respectively, with a plateau starting at 6 years ( Figure 1) . No significant outcome differences were noted by patient and disease characteristics (details not shown). Our data compare favorably with results reported from others, [2] [3] [4] [5] [6] both in terms of follow-up and number of patients, and are among the longest follow-ups reported in this kind of lymphoma. Furthermore, they add evidence that in vivo purging, HPC transplantation and immunotherapy for MRD may lead to improved outcomes in patients with rFL, and that a response-adapted therapy and conditioning with chemotherapy alone instead of combination with TBI can decrease toxicity. 
